Takeda Pharmaceutical Company Limited (FRA:TKD)
Germany
· Delayed Price · Currency is EUR 24.40
+0.19 (0.78%)
At close: Dec 5, 2025
Revenue Breakdown
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Gastroenterology Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Rare Metabolic Revenue | - |
Log In |
Log In |
Log In | Upgrade
|
| Rare Hematology Revenue | - |
Log In |
Log In |
Log In | Upgrade
|
| Hereditary Angioedema Revenue | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Rare Disease Revenue | - |
Log In |
Log In |
Log In | Upgrade
|
| Rare Genetics and Other Revenue | - |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| PDT Immunology Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| GI Revenue (Post-FY2024 Reporting) | 1,354.60B | 1,357.02B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Revenue (Post-FY2024 Reporting) | 744.60B | 752.82B |
Log In |
Log In |
Log In | Upgrade
|
| PDT Revenue (Post-FY2024 Reporting) | 1,014.60B | 1,032.66B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue (Post-FY2024 Reporting) | 563.30B | 560.43B |
Log In |
Log In |
Log In | Upgrade
|
| Vaccines Revenue | 49.00B | 55.41B |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue (Post-FY2024 Reporting) | 457.30B | 565.82B |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue (Post-FY2024 Reporting) | 233.70B | 257.39B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Japan Revenue | 421.20B | 418.46B |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue | 2,224.00B | 2,379.65B |
Log In |
Log In |
Log In | Upgrade
|
| Europe and Canada Revenue | 1,057.50B | 1,055.25B |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Revenue | 221.80B | 235.85B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | - | 191.74B |
Log In |
Log In |
Log In | Upgrade
|
| Asia (ex-Japan & China) Revenue | 97.30B | 99.39B |
Log In |
Log In |
Log In | Upgrade
|
| Asia (ex-Japan) Revenue | 291.50B | 291.13B |
Log In |
Log In |
Log In | Upgrade
|
| Russia / CIS Revenue | 72.60B | 72.36B |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographic Revenue | 128.50B | 128.85B |
Log In |
Log In |
Log In | Upgrade
|